The Zero Childhood Cancer Initiative aims to use genomics to develop personalized therapeutic strategies for currently untreatable pediatric cancers.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
Richard Wilson and Elaine Mardis plan to use comprehensive sequencing to transition genomic discoveries into clinical assays for pediatric cancer and germline disorders.
The companies will combine Qiagen's QIAxcel and CareDx's Olerup SSP kits and Score software into an HLA typing product offering for transplant labs.
Through the deal, the partners will offer tailored genomic guidance on nutrition, fitness, skin care, and other wellness topics to customers.
The company said its new Massachusetts office will focus on driving US sales of its Proseek Multiplex platform for targeted human protein biomarker discovery.
Last week, GenomeWeb's readers were most interested in a study showing that the genetic risk of breast cancer can be mitigated by certain lifestyle changes.
An international research team resequenced the genomes of 50 orcas to learn how genetics influenced the evolution of the species' different ecotypes.
The Canadian firm will be announcing a menu for the Spartan Cube at August's American Association of Clinical Chemistry conference and will seek CLIA waiver.
Canadian researchers have added to the growing body of evidence supporting the use of sequencing to diagnose suspected genetic disorders in newborns admitted to the NICU.
The firm has taken full ownership of its CLIA-certified joint venture laboratory in a bid to bail it out, and is raising money to continue operations.
Biocept has launched its first test for use in guiding cancer immunotherapies, a PD-L1 protein expression assay performed on circulating tumor cells. The CLIA-validated test, developed by Biocept scientists in collaboration with Yale University School of Medicine's David Rimm, is intended to be used to detect and monitor PD-L1 protein expression throughout the course of a patient's treatment with newly approved immuno-oncologic drugs.
A collaboration between the Broad Institute and Microsoft Research has created machine learning-derived rules to improve on-target efficiency.
The company said FEI's technology will complement its mass spectrometry business, particularly in its work on structural proteins and biopharmaceuticals.
Using 16S ribosomal RNA sequencing, researchers identified bacteria and archaea in the gastrointestinal tract of four North American beavers.
At a user meeting in London this week, Chief Technology Officer Clive Brown introduced the SmidgIon and a number of other technology developments, as well as a new synthetic biology spinoff.